Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756423 | 0.86 | TLR7 (0.43) | TLR7MEN1NPC1GAARAB9A | |
| SCHEMBL5405185 | 0.85 | XBP1 (0.48) | TLR7XBP1CNR2CNR1HTT | |
| SCHEMBL6494409 | 0.84 | TLR7 (0.54) | TLR7GAATLR8HTTLMNA | |
| SCHEMBL4551314 | 0.84 | TLR7 (0.54) | TLR7GAAHTTSMN1; SMN2LMNA | |
| SCHEMBL24183914 | 0.84 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL24723244 | 0.83 | TLR7 (0.54) | TLR7GAATLR8HTTSMN1; SMN2 | |
| SCHEMBL4756373 | 0.83 | KMT2A (0.45) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL24183911 | 0.82 | TLR7 (0.49) | TLR7TLR8SMN1; SMN2 | |
| SCHEMBL29136618 | 0.81 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL30824675 | 0.81 | TLR7 (0.60) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605943-A4 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7163947-B2 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| CN-1784231-A | 1-amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-06-07 | — | — | CN | disclosed |
| WO-2006028451-A1 | 1-AMINO 1-H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1605943-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | TLR7 146/4885XBP1 2826/4885MEN1 2757/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | TLR7 146/4885XBP1 2826/4885MEN1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.